Chemotherapy-free treatment option to be offered to patients with England’s most common leukaemia
Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.
Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.
NICE has today (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF).
People with chronic primary pain should be offered a range of treatments to help them manage their condition.
One year on from the first national lockdown, NICE has today (23 March) published a single guideline for the management of COVID-19 in children and adults.
A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer will now be available on the Cancer Drugs Fund (CDF), following its approval by NICE in draft guidance published today.
New draft guidance from NICE recommends children and young people are fully informed about their health so that they can take an active role in their healthcare.
Page 43 of 46